drugset / Trial / NCT05549037
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
Timeline
- Start
- 2022-09-23
- Primary completion
- 2024-12-02
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |